Sudo Biosciences

Carmel, United States

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

$30.0M raised

Feb 2024

Series B

Biopharma Biotechnology Health Care Life Science Medical

Top Investors

TPG Dementia Discovery Fund Frazier Life Sciences Sanofi Ventures Enavate Sciences

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Sudo Biosciences

How much funding has Sudo Biosciences raised?

Sudo Biosciences has raised $30.0M in total funding. The most recent round was Series B. The last funding was announced in February 2024.

Who are Sudo Biosciences's investors?

Sudo Biosciences's investors include TPG, Dementia Discovery Fund, Frazier Life Sciences, Sanofi Ventures, Enavate Sciences.

Where is Sudo Biosciences headquartered?

Sudo Biosciences is headquartered in Carmel, United States.

What does Sudo Biosciences do?

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

What stage is Sudo Biosciences at?

Sudo Biosciences is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 13, 2024.

MLA

"Sudo Biosciences — Funding & Investors." VCBacked, February 13, 2024, https://www.vcbacked.co/company/sudo-biosciences. Accessed July 2, 2026.

APA

VCBacked. (2024). Sudo Biosciences — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/sudo-biosciences

Wikipedia (cite web)

{{cite web |title=Sudo Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/sudo-biosciences |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 13, 2024.

Similar Companies in Biopharma

View all

Allterum Therapeutics

Living In Silico Inc.